Regular lipoprotein apheresis (LA) is associated with a decrease in cardiovascular (CV) events in patients with Lp(a) >60 mg/dL and progressive atherosclerotic cardiovascular disease (ASCVD). This is the finding from the observational multicentre Pro(a)LiFestudy of consecutive patients with high Lp(a) and progressive ASCVD despite effective treatment of other ASCVD risk factors.
